Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Ullrich NJ"" wg kryterium: Autor


Tytuł :
The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
Autorzy :
Blakeley, JO
Bakker, A
Barker, A
Clapp, W
Ferner, R
Fisher, MJ
Giovannini, M
Gutmann, DH
Karajannis, MA
Kissil, JL
Legius, E
Lloyd, AC
Packer, RJ
Ramesh, V
Riccardi, VM
Stevenson, DA
Ullrich, NJ
Upadhyaya, M
Stemmer-Rachamimov, A
Pokaż więcej
Temat :
rare disease
therapeutic discovery
Neurofibromatoses
schwannomatosis
Skin Neoplasms
pediatric tumors
Genetics
Neurilemmoma
Pediatrics
neurofibromatosis type 1
neurofibromatosis type 2
Clinical Sciences
Neurofibromatosis 2
Humans
Neurofibromatosis 1
Child
Źródło :
American journal of medical genetics. Part A, vol 173, iss 6
Blakeley, JO; Bakker, A; Barker, A; Clapp, W; Ferner, R; Fisher, MJ; et al.(2017). The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis. AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 173(6), 1714 - 1721. doi: 10.1002/ajmg.a.38239. UCLA: Retrieved from: http://www.escholarship.org/uc/item/32t721k9
Opis pliku :
application/pdf
Tytuł :
Long-term neurocognitive and quality of life outcomes in survivors of pediatric hematopoietic cell transplant.
Autorzy :
Wu NL; Department of Pediatrics, Division of Hematology/Oncology, University of Washington, Seattle Children's Hospital, 4600 Sand Point Way NE, Seattle, WA, 98105, USA. .; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., P.O. Box 19024, Seattle, WA, 98109, USA. .
Krull KR; Department of Epidemiology and Cancer Control, Department of Psychology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA.
Cushing-Haugen KL; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., P.O. Box 19024, Seattle, WA, 98109, USA.
Ullrich NJ; Department of Neurology, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA.
Kadan-Lottick NS; Department of Pediatrics, Yale University School of Medicine, Yale Cancer Center, PO Box 208028, New Haven, CT, 06520, USA.
Lee SJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., P.O. Box 19024, Seattle, WA, 98109, USA.
Chow EJ; Department of Pediatrics, Division of Hematology/Oncology, University of Washington, Seattle Children's Hospital, 4600 Sand Point Way NE, Seattle, WA, 98105, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., P.O. Box 19024, Seattle, WA, 98109, USA.
Pokaż więcej
Źródło :
Journal of cancer survivorship : research and practice [J Cancer Surviv] 2021 Jun 04. Date of Electronic Publication: 2021 Jun 04.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact.
Autorzy :
Phillips NS; Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN.
Duke ES; Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC.
Schofield HT; Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, PA.; Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA.
Ullrich NJ; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Jun 01; Vol. 39 (16), pp. 1752-1765. Date of Electronic Publication: 2021 Apr 22.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1.
Autorzy :
Payne JM; Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.; University of Melbourne, Parkville, Victoria, Australia.
Haebich KM; Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.
MacKenzie R; La Trobe University, Bundoora, Victoria, Australia.
Walsh KS; Children's National Health System, Washington, DC, USA.
Hearps SJC; Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.
Coghill D; Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.; University of Melbourne, Parkville, Victoria, Australia.
Barton B; The Children's Hospital at Westmead, New South Wales, Australia.; The University of Sydney, New South Wales, Australia.
Pride NA; The Children's Hospital at Westmead, New South Wales, Australia.; The University of Sydney, New South Wales, Australia.
Ullrich NJ; Boston Children's Hospital, MA, USA.
Tonsgard JH; The University of Chicago Medicine Comer Children's Hospital, IL, USA.
Viskochil D; The University of Utah, Salt Lake City, USA.
Schorry EK; Cincinnati Children's Hospital Medical Center, OH, USA.
Klesse L; University of Texas Southwestern Medical Center, Dallas, USA.
Fisher MJ; Children's Hospital of Philadelphia, PA, USA.
Gutmann DH; Washington University School of Medicine, St Louis, MO, USA.
Rosser T; Children's Hospital Los Angeles, CA, USA.
Packer RJ; Children's National Health System, Washington, DC, USA.
Korf B; The University of Alabama at Birmingham, USA.
Acosta MT; Children's National Health System, Washington, DC, USA.
Bellgrove MA; Monash University, Clayton, Victoria, Australia.
North KN; Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.; University of Melbourne, Parkville, Victoria, Australia.
Pokaż więcej
Źródło :
Journal of attention disorders [J Atten Disord] 2021 Jun; Vol. 25 (8), pp. 1177-1186. Date of Electronic Publication: 2019 Dec 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Attention Deficit Disorder with Hyperactivity*/epidemiology
Neurofibromatosis 1*/complications
Neurofibromatosis 1*/epidemiology
Adolescent ; Child ; Cognition ; Executive Function ; Humans ; Neuropsychological Tests ; Quality of Life
Czasopismo naukowe
Tytuł :
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.
Autorzy :
Legius E; Department of Human Genetics, KU Leuven and University Hospital, Leuven, Belgium. .
Messiaen L; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
Wolkenstein P; Assistance Publique-Hôpital Paris (AP-HP), Hôpital Henri-Mondor, UPEC, Service de Dermatologie, Créteil, France.
Pancza P; Children's Tumor Foundation, New York, NY, USA.
Avery RA; Division of Ophthalmology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Berman Y; Clinical Genetics, Royal North Shore Hospital, St. Leonards, NSW, Australia and University of Sydney, Sydney, Australia.
Blakeley J; Johns Hopkins Comprehensive Neurofibromatosis Center, Baltimore, MD, USA.
Babovic-Vuksanovic D; Department of Clinical Genomics, Mayo Clinic College of Medicine, Rochester, MN, USA.
Cunha KS; Department of Pathology, Universidade Federal Fluminense, Niteroi, Brasil.
Ferner R; Neurology, Guy's and St. Thomas' Hospital and NHS Trust, London, UK.
Fisher MJ; Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Friedman JM; Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Gutmann DH; Neurology, Washington University, St. Louis, MO, USA.
Kehrer-Sawatzki H; Institute of Human Genetics, University of Ulm, Ulm, Germany.
Korf BR; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
Mautner VF; Neurology, University Hospital of Hamburg-Eppendorf, Hamburg, Germany.
Peltonen S; Dermatology, University of Turku and Turku University Hospital, Turku, Finland.; Department of Dermatology and Venereology, University of Gothenburg, Gothenburg, Sweden.
Rauen KA; Pediatrics, University of California Davis, Sacramento, CA, USA.
Riccardi V; The Neurofibromatosis Institute, La Crescenta, CA, USA.
Schorry E; Medical Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Stemmer-Rachamimov A; Neuropathology, Massachusetts General Hospital, Boston, MA, USA.
Stevenson DA; Medical Genetics, Stanford University, Stanford, CA, USA.
Tadini G; Pediatric Dermatology, University of Milan, Milan, Italy.
Ullrich NJ; Department of Neurology, Boston Children's Hospital, Boston, MA, USA.
Viskochil D; Medical Genetics, University of Utah, Salt Lake City, UT, USA.
Wimmer K; Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
Yohay K; NYU Langone Health, New York, NY, USA.
Huson SM; Clinical Genetics, (Formerly) Manchester Center for Genomic Medicine, Manchester University Hospitals, NHS Foundation Trust, Manchester, UK.
Evans DG; Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK.
Plotkin SR; Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
Pokaż więcej
Corporate Authors :
International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC)
Źródło :
Genetics in medicine : official journal of the American College of Medical Genetics [Genet Med] 2021 May 19. Date of Electronic Publication: 2021 May 19.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
Autorzy :
Bowers DC; Division of Pediatric Hematology/Oncology, Harold C Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: .
Verbruggen LC; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Kremer LCM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Hudson MM; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.
Skinner R; Department of Paediatric and Adolescent Haematology and Oncology, Great North Children's Hospital, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.
Constine LS; Department of Radiation Oncology, Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, USA.
Sabin ND; Department of Diagnostic Imaging, St Jude Children's Research Hospital, Memphis, TN, USA.
Bhangoo R; Neurosurgical Department, King's College Hospital Foundation Trust, London, UK.
Haupt R; Epidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Hawkins MM; Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Jenkinson H; Department of Paediatric Oncology, Birmingham Children's Hospital, Birmingham, UK.
Khan RB; Department of Pediatrics, Division of Neurology, St Jude Children's Research Hospital, Memphis, TN, USA.
Klimo P Jr; Department of Neurosurgery, University of Tennessee, Memphis, TN, USA.
Pretorius P; Department of Neuroradiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Ng A; Department of Paediatric Oncology, Royal Hospital for Children, Bristol, UK.
Reulen RC; Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Ronckers CM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Institute for Biostatistics and Registry Research, Brandenburg Medical School, Neuruppin, Germany.
Sadighi Z; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Scheinemann K; Division of Oncology-Hematology, Department of Pediatrics, Kantonsspital Aarau, Switzerland; Division of Hematology & Oncology, University Children's Hospital Basel, University of Basel, Switzerland; Department of Pediatrics, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada.
Schouten-van Meeteren N; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Sugden E; North Hinksey Village, Oxford, UK.
Teepen JC; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Ullrich NJ; Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Walter A; Department of Pediatrics, Sidney Kimmel Medical College, Thomas Jefferson University, Wilmington, DE, USA; Department of Pediatrics, A I duPont Hospital for Children, Wilmington, DE, USA.
Wallace WH; Department of Paediatric Oncology, Royal Hospital for Sick Children, Edinburgh, UK.
Oeffinger KC; Department of Community and Family Medicine, Duke University School of Medicine, Durham, NC, USA.
Armstrong GT; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.
van der Pal HJH; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Mulder RL; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 May; Vol. 22 (5), pp. e196-e206. Date of Electronic Publication: 2021 Apr 09.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Cancer Survivors*
Practice Guidelines as Topic*
Central Nervous System Neoplasms/*etiology
Adolescent ; Central Nervous System Neoplasms/diagnosis ; Child ; Early Detection of Cancer ; Humans ; Young Adult
Czasopismo naukowe
Tytuł :
Outcomes after first relapse of childhood intracranial ependymoma.
Autorzy :
Tsai JW; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.
Manoharan N; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.; Kids Cancer Centre, Sydney Children's Hospital, Sydney, New South Wales, Australia.
Alexandrescu S; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.; Department of Pathology, Boston Children's Hospital, Boston, Massachusetts, USA.
Zimmerman MA; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.
Scully J; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.
Chordas C; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.
Clymer J; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.
Wright KD; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.
Filbin M; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.
Ullrich NJ; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.; Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA.
Marcus KJ; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.; Division of Radiation Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Haas-Kogan D; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.; Division of Radiation Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Chi SN; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.
Bandopadhayay P; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.
Yeo KK; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.
Pokaż więcej
Źródło :
Pediatric blood & cancer [Pediatr Blood Cancer] 2021 Aug; Vol. 68 (8), pp. e28930. Date of Electronic Publication: 2021 Feb 09.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children.
Autorzy :
Ullrich NJ; Department of Neurology, Boston Children's Hospital, Boston, Massachusetts.; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts.
Prabhu SP; Department of Radiology, Boston Children's Hospital, Boston, Massachusetts.
Packer RJ; Center for Neuroscience and Behavioral Medicine, Children's National Hospital, Washington, District of Columbia.
Goldman S; Ann and Robert Lurie Children's Hospital, Chicago, Illinois.
Robison NJ; Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California.
Allen JC; Departments of Pediatrics and Neurology, NYU Langone Medical Center, New York, New York.
Viskochil DH; Department of Genetics, University of Utah, Salt Lake City, Utah.
Gutmann DH; Department of Neurology, Washington University School of Medicine, St Louis, Missouri.
Perentesis JP; Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Korf BR; Department of Medical Genetics, University of Alabama at Birmingham, Birmingham, Alabama.
Fisher MJ; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Kieran MW; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts.
Pokaż więcej
Corporate Authors :
NF Clinical Trials Consortium
Źródło :
Pediatric blood & cancer [Pediatr Blood Cancer] 2021 Apr; Vol. 68 (4), pp. e28833. Date of Electronic Publication: 2020 Dec 18.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research.
Autorzy :
Radtke HB; Children's Tumor Foundation, New York, NY, USA. .; Medical College of Wisconsin, Milwaukee, WI, USA. .
Klein-Tasman BP; University of WI - Milwaukee, Milwaukee, WI, USA.
Merker VL; Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, USA.
Knight P; Children's Tumor Foundation, New York, NY, USA.
Ullrich NJ; Boston Children's Hospital, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.
Jordan JT; Massachusetts General Hospital, Boston, MA, USA.
Korf B; University of Alabama At Birmingham, Birmingham, AL, USA.
Plotkin SR; Massachusetts General Hospital, Boston, MA, USA.
Pokaż więcej
Źródło :
Orphanet journal of rare diseases [Orphanet J Rare Dis] 2021 Feb 01; Vol. 16 (1), pp. 61. Date of Electronic Publication: 2021 Feb 01.
Typ publikacji :
Letter
MeSH Terms :
COVID-19/*epidemiology
Neurofibromatoses/*epidemiology
SARS-CoV-2/*pathogenicity
Telemedicine/*methods
Humans ; Pandemics/statistics & numerical data ; Patient Satisfaction ; Rare Diseases ; United States
Opinia redakcyjna
Tytuł :
Novel predictive scoring system for morbid hypothalamic obesity in patients with pediatric craniopharyngioma.
Autorzy :
Fouda MA; Department of Neurosurgery, Boston Children's Hospital, Boston, MA, USA. .; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. .
Zurakowski D; Division of Biostatistics, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA, USA.
Scott RM; Department of Neurosurgery, Boston Children's Hospital, Boston, MA, USA.
Marcus KJ; Division of Radiation Oncology, Boston Children's Hospital, Boston, MA, USA.; Dana Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Manley PE; Division of Endocrinology, Boston Children's Hospital, Boston, MA, USA.
Ullrich NJ; Dana Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Department of Neurology, Boston Children's Hospital, Boston, MA, USA.
Cohen LE; Division of Endocrinology, Boston Children's Hospital, Boston, MA, USA.
Goumnerova LC; TromboProtea Inc, Boston, MA, USA.
Pokaż więcej
Źródło :
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery [Childs Nerv Syst] 2021 Feb; Vol. 37 (2), pp. 403-410. Date of Electronic Publication: 2020 Sep 04.
Typ publikacji :
Journal Article
MeSH Terms :
Craniopharyngioma*/complications
Craniopharyngioma*/surgery
Obesity, Morbid*/complications
Pituitary Neoplasms*/complications
Pituitary Neoplasms*/surgery
Body Mass Index ; Child ; Female ; Follow-Up Studies ; Humans ; Male ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Neuro-Oncology Training for the Child Neurology Resident.
Autorzy :
Malbari F; Texas Children's Hospital, 3989Baylor College of Medicine, Houston, TX, USA.
Partap S; Lucile Packard Children's Hospital, 6429Stanford University, Palo Alto, CA, USA.
Gust J; Seattle Children's, University of Washington, Seattle, WA, USA.
Duke E; 8404Children's National Medical Center, Washington, DC, USA.
Sato A; Seattle Children's, University of Washington, Seattle, WA, USA.
Khakoo Y; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College New York, NY, USA.
Ullrich NJ; Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Pokaż więcej
Źródło :
Journal of child neurology [J Child Neurol] 2021 Jan; Vol. 36 (1), pp. 79-82. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
Autorzy :
Fisher MJ; Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Shih CS; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.; Merck & Co., Inc., Kenilworth, NJ, USA.
Rhodes SD; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Armstrong AE; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.; Division of Pediatric Hematology/Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Wolters PL; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Dombi E; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Zhang C; Department of Medical and Molecular Genomics, Indiana University, Indianapolis, IN, USA.
Angus SP; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.; Department of Pharmacology, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.; Department of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Johnson GL; Department of Pharmacology, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.
Packer RJ; Center for Neuroscience and Behavioral Medicine, Children's National Medical Center, Washington, DC, USA.
Allen JC; Department of Pediatrics, New York University School of Medicine, New York, NY, USA.
Ullrich NJ; Department of Neurology, Dana Farber/Boston Children's Hospital, Boston, MA, USA.
Goldman S; Division of Hematology/Oncology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Gutmann DH; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Plotkin SR; Department of Neurology and Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA.
Rosser T; Division of Neurology, Children's Hospital of Los Angeles, Los Angeles, CA, USA.
Robertson KA; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.
Widemann BC; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Smith AE; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Bessler WK; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
He Y; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Park SJ; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Mund JA; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Jiang L; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Bijangi-Vishehsaraei K; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.
Robinson CT; Department of Biostatistics, University of Alabama Birmingham, Birmingham, AL, USA.
Cutter GR; Department of Biostatistics, University of Alabama Birmingham, Birmingham, AL, USA.
Korf BR; Department of Genetics, University of Alabama Birmingham, Birmingham, AL, USA.
Blakeley JO; Department of Neurology, Johns Hopkins University, Baltimore, MD, USA. .
Clapp DW; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA. .; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA. .
Pokaż więcej
Corporate Authors :
Neurofibromatosis Clinical Trials Consortium
Źródło :
Nature medicine [Nat Med] 2021 Jan; Vol. 27 (1), pp. 165-173. Date of Electronic Publication: 2021 Jan 13.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :
Anilides/*therapeutic use
Neurofibroma, Plexiform/*drug therapy
Neurofibromatosis 1/*drug therapy
Pyridines/*therapeutic use
Adolescent ; Adult ; Anilides/adverse effects ; Anilides/pharmacokinetics ; Animals ; Disease Models, Animal ; Female ; Genes, Neurofibromatosis 1 ; Humans ; Male ; Mice ; Mice, Mutant Strains ; Neurofibroma, Plexiform/genetics ; Neurofibroma, Plexiform/pathology ; Neurofibromatosis 1/genetics ; Neurofibromatosis 1/pathology ; Pain Measurement ; Prospective Studies ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Kinase Inhibitors/therapeutic use ; Pyridines/adverse effects ; Pyridines/pharmacokinetics ; Quality of Life ; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors ; Translational Medical Research ; Young Adult
Czasopismo naukowe
Tytuł :
Are Some Randomized Clinical Trials Impossible?
Autorzy :
Rios JJ; Center for Pediatric Bone Biology and Translational Research, Scottish Rite for Children.; McDermott Center for Human Growth and Development.; Departments of Pediatrics.; Orthopaedic Surgery, UT Southwestern Medical Center.
Richards BS; Orthopaedic Surgery, UT Southwestern Medical Center.; Department of Orthopaedics, Scottish Rite for Children, Dallas, TX.
Stevenson DA; Department of Pediatrics, Stanford University, Stanford.
Oberlander B; Neurofibromatosis Network, Wheaton, IL.
Viskochil D; Department of Pediatrics, University of Utah, Salt Lake City, UT.
Gross AM; Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD.
Dombi E; Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD.
Widemann BC; Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD.
Plotkin SR; Department of Neurology and Cancer Center, Massachusetts General Hospital.
May CJ; Departments of Orthopaedics.
Ullrich NJ; Neurology, Boston Children's Hospital, Boston, MA.
Goldstein RY; Department of Orthopaedics, Children's Hospital Los Angeles, Los Angeles, CA.
Jain V; Divisions of Orthopaedics.
Schorry EK; Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH.
Pokaż więcej
Corporate Authors :
NFCTC Consortium
Źródło :
Journal of pediatric orthopedics [J Pediatr Orthop] 2021 Jan; Vol. 41 (1), pp. e90-e93.
Typ publikacji :
Journal Article
MeSH Terms :
Patient Selection*
Pseudarthrosis*/congenital
Pseudarthrosis*/surgery
Bone Morphogenetic Protein 2/*pharmacology
Neurofibromatosis 1/*surgery
Orthopedic Procedures/*methods
Randomized Controlled Trials as Topic/*methods
Transforming Growth Factor beta/*pharmacology
Bone Morphogenetic Proteins/pharmacology ; Humans ; Neurofibromatosis 1/complications ; Rare Diseases ; Recombinant Proteins/pharmacology ; Sample Size ; Tibia/abnormalities ; Tibia/surgery
Czasopismo naukowe
Tytuł :
Visual field outcomes in children treated for neurofibromatosis type 1-associated optic pathway gliomas: a multicenter retrospective study.
Autorzy :
Heidary G; Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: .
Fisher MJ; Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Liu GT; Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Ferner RE; Guy's and St. Thomas' Hospital, London, United Kingdom.
Gutmann DH; St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, Missouri.
Listernick RH; Ann & Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Kapur K; Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Loguidice M; Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Ardern-Holmes SL; The Children's Hospital at Westmead, Sydney, Australia.
Avery RA; Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Children's National Medical Center, Washington, District of Columbia.
Hammond C; Guy's and St. Thomas' Hospital, London, United Kingdom.
Hoffman RO; Moran Eye Center, University of Utah, Salt Lake City, Utah.
Hummel TR; Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Kuo A; Moran Eye Center, University of Utah, Salt Lake City, Utah.
Reginald A; The Hospital for Sick Children, Toronto, Ontario, Canada.
Ullrich NJ; Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Pokaż więcej
Źródło :
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus [J AAPOS] 2020 Dec; Vol. 24 (6), pp. 349.e1-349.e5. Date of Electronic Publication: 2020 Nov 20.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey.
Autorzy :
Orgel E; Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California.; Keck School of Medicine, University of Southern California, Los Angeles, California.
Freyer DR; Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California.; Keck School of Medicine, University of Southern California, Los Angeles, California.
Ullrich NJ; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
Hardy KK; Children's National Hospital, Washington, District of Columbia.; George Washington University School of Medicine, Washington, District of Columbia.
Thomas SM; Cleveland Clinic Children's, Cleveland, Ohio.
Dvorak CC; UCSF Benioff Children's Hospital, San Francisco, California.
Esbenshade AJ; Vanderbilt University Ingram Cancer Center, Nashville, Tennessee.
Pokaż więcej
Źródło :
Pediatric blood & cancer [Pediatr Blood Cancer] 2020 Nov; Vol. 67 (11), pp. e28647. Date of Electronic Publication: 2020 Sep 04.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*adverse effects
Cisplatin/*adverse effects
Hearing Loss/*prevention & control
Neoplasms/*drug therapy
Thiosulfates/*therapeutic use
Adolescent ; Antioxidants/therapeutic use ; Child ; Follow-Up Studies ; Hearing Loss/chemically induced ; Hearing Loss/pathology ; Humans ; Neoplasms/pathology ; Prognosis ; Surveys and Questionnaires
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies